丹諾醫藥(蘇州)股份有限公司 (06872.HK)

TenNor Therapeutics Suzhou Ltd. manufactures pharmaceutical products. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2026-05-22. The firm focuses on the fields of bacterial infections and bacterial metabolism diseases. The firm's products include Rifasutenizol (TNP-2198), a novel molecular entity candidate for the treatment of Helicobacter pylori, Rifaquizinone (TNP-2092) injection, a triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections and TNP-2092 oral, multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.